Buprenorphine Maintenance Therapy Hinders Acute Pain Management in Trauma

2010 ◽  
Vol 76 (4) ◽  
pp. 397-399 ◽  
Author(s):  
Colin J. Harrington ◽  
Victor Zaydfudim

Buprenorphine is a mixed opiate receptor agonist-antagonist growing in popularity as an office-based treatment for opioid-dependent patients. It has high affinity, but only partial agonism at the μ-opioid receptor resulting in a ceiling analgesic effect. At higher doses, buprenorphine potentiates antagonism at the κ-opioid receptor. These properties make buprenorphine an effective maintenance treatment for opioid-dependent patients. These same properties, however, can interfere with the management of acute pain in patients on maintenance buprenorphine therapy. We present a case of a young multisystem trauma patient in whom adequate analgesia could not be achieved due to buprenorphine treatment before and through the early course of admission. Discontinuation of buprenorphine allowed for appropriate pain management and successful analgesia. Further education of acute care clinicians about buprenorphine pharmacology and careful selection of patients for buprenorphine maintenance therapy are needed to avoid delays of pain control in trauma patients.

2021 ◽  
Vol 50 (1) ◽  
pp. 781-781
Author(s):  
Justin Culshaw ◽  
Carolyn Philpott ◽  
Krissy Reinstatler ◽  
Paige Bradshaw ◽  
Marisa Brizzi ◽  
...  

Pain ◽  
2016 ◽  
Vol 157 (1) ◽  
pp. 264-272 ◽  
Author(s):  
Eugene R. Viscusi ◽  
Lynn Webster ◽  
Michael Kuss ◽  
Stephen Daniels ◽  
James A. Bolognese ◽  
...  

2020 ◽  
Vol 21 (22) ◽  
pp. 8463
Author(s):  
Damian Bartuzi ◽  
Ewa Kędzierska ◽  
Agnieszka A. Kaczor ◽  
Helmut Schmidhammer ◽  
Dariusz Matosiuk

Opioids are the drugs of choice in severe pain management. Unfortunately, their use involves serious, potentially lethal side effects. Therefore, efforts in opioid drug design turn toward safer and more effective mechanisms, including allosteric modulation. In this study, molecular dynamics simulations in silico and ‘writhing’ tests in vivo were used to characterize potential allosteric mechanism of two previously reported compounds. The results suggest that investigated compounds bind to μ opioid receptor in an allosteric site, augmenting action of morphine at subeffective doses, and exerting antinociceptive effect alone at higher doses. Detailed analysis of in silico calculations suggests that first of the compounds behaves more like allosteric agonist, while the second compound acts mainly as a positive allosteric modulator.


2021 ◽  
Author(s):  
Thaddeus J Puzio ◽  
James Klugh ◽  
Michael W Wandling ◽  
Charles Green ◽  
Julius Balogh ◽  
...  

Abstract BackgroundEvidence for effective pain management and opioid minimization of intravenous ketamine in elective surgery has been extrapolated to acutely injured patients, despite limited supporting evidence in this population. This trial seeks to determine the effectiveness of the addition of sub-dissociative ketamine to a pill-based, opioid-minimizing multi-modal pain regimen (MMPR) for post traumatic pain.MethodsThis is a single-center, parallel-group, randomized, controlled comparative effectiveness trial comparing a MMPR to a MMPR plus a sub-dissociative ketamine infusion. All trauma patients 16 years and older admitted following a trauma which require intermediate (IMU) or intensive care unit (ICU) level of care are eligible. Prisoners, patients who are pregnant, patients not expected to survive, and those with contraindications to ketamine are excluded from this study. The primary outcome is opioid use, measured by morphine milligram equivalents (MME) per patient per day (MME/patient/day). The secondary outcomes include total MME, pain scores, morbidity, lengths of stay, opioid prescriptions at discharge, and patient centered outcomes at discharge and six months.DiscussionThis trial will determine the effectiveness of sub-dissociative ketamine infusion as part of a MMPR in reducing in-hospital opioid exposure in adult trauma patients. Furthermore, it will inform decisions regarding acute pain strategies on patient centered outcomes.Trial Registration:The Ketamine for Acute Pain Management After Trauma (KAPT) with registration # NCT04129086 was registered on 10/16/2019 and is available at https://clinicaltrials.gov/ct2/show/NCT04129086?term=ketamine+injury&draw=2&rank=6


Sign in / Sign up

Export Citation Format

Share Document